Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

G Protein-coupled Receptors01:15

G Protein-coupled Receptors

G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Acetylation-Primed SUMOylation Drives RORβ Turnover via a p300-SIRT1 Regulatory Axis.

bioRxiv : the preprint server for biology·2026
Same author

Preclinical characterization of EGT710, an oral non-peptidomimetic reversible covalent SARS-CoV-2 main protease inhibitor.

npj drug discovery·2026
Same author

PyMACS: A python-based automation suite for GROMACS molecular dynamics setup, simulation, and analysis.

European journal of medicinal chemistry·2026
Same author

Stalling the Enemy: Targeting Nsp13 for Next-Generation SARS-CoV-2 Antivirals.

International journal of molecular sciences·2026
Same author

Editor's Note: The Genetic Landscape of Ocular Adnexa MALT Lymphoma Reveals Frequent Aberrations in NFAT and MEF2B Signaling Pathways.

Cancer research communications·2026
Same author

Advancing the bioassay ontology through integrated PK/PD and safety pharmacology representation.

Journal of biomedical semantics·2026

Related Experiment Video

Updated: Jun 6, 2026

Parallel Interrogation of β-Arrestin2 Recruitment for Ligand Screening on a GPCR-Wide Scale using PRESTO-Tango Assay
09:03

Parallel Interrogation of β-Arrestin2 Recruitment for Ligand Screening on a GPCR-Wide Scale using PRESTO-Tango Assay

Published on: March 10, 2020

A combined ligand- and structure-based virtual screening protocol identifies submicromolar PPARγ partial agonists.

Dušica Vidović1, Scott A Busby, Patrick R Griffin

  • 1Center for Computational Science, University of Miami, FL 33136, USA.

Chemmedchem
|December 17, 2010
PubMed
Summary

Researchers identified new potential antidiabetic drugs by screening compounds for Peroxisome proliferator-activated receptor gamma (PPARγ) partial agonism. This approach aims for effective glucose and lipid metabolism control without severe side effects.

More Related Videos

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English
14:34

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

Published on: April 3, 2026

Related Experiment Videos

Last Updated: Jun 6, 2026

Parallel Interrogation of β-Arrestin2 Recruitment for Ligand Screening on a GPCR-Wide Scale using PRESTO-Tango Assay
09:03

Parallel Interrogation of β-Arrestin2 Recruitment for Ligand Screening on a GPCR-Wide Scale using PRESTO-Tango Assay

Published on: March 10, 2020

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English
14:34

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

Published on: April 3, 2026

Area of Science:

  • Pharmacology
  • Medicinal Chemistry
  • Molecular Biology

Background:

  • Peroxisome proliferator-activated receptor gamma (PPARγ) regulates glucose and lipid metabolism.
  • Thiazolidinediones (TZDs) target PPARγ for diabetes treatment but cause adverse effects due to full receptor activation.
  • Developing PPARγ partial agonists offers a strategy for improved antidiabetic therapies with fewer side effects.

Purpose of the Study:

  • To identify novel lead compounds with PPARγ partial agonist activity.
  • To develop a virtual screening protocol for efficient discovery of PPARγ modulators.
  • To find potential candidates for next-generation antidiabetic drugs.

Main Methods:

  • Utilized a virtual screening protocol combining three-dimensional ligand-shape similarity and molecular docking.
  • Screened 340,000 compounds from the NIH Molecular Libraries Small Molecule Repository (MLSMR).
  • Prioritized 235 compounds for experimental validation through cell-based transactivation and competitive binding assays.

Main Results:

  • Confirmed seven novel potent partial agonists of PPARγ.
  • Demonstrated the success of the virtual screening strategy in identifying promising drug leads.
  • Validated compounds exhibit potential for therapeutic development in diabetes.

Conclusions:

  • The virtual screening campaign successfully identified novel PPARγ partial agonists.
  • These compounds represent potential starting points for developing safer and more effective antidiabetic medications.
  • This study highlights the utility of computational methods in drug discovery for metabolic diseases.